SecBot SecBot

SCTX

Scribe Therapeutics, Inc.
Nasdaq· CIK 0001853921 Biotech & Drug Discovery
$15.89 +0.29 (+1.86%)
Oct 27 4:00 PM ET · prev $15.60
Market cap
$291.6M
Micro cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$59.00
+271% · range $50.00–60.00
Since first trade
−16.2%
from $18.97 · Jul 27
30 days
−27.0%
from $21.77
Range since listing
$15.41–37.25
−57% from high · low Oct 23
Avg volume 20D
494.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$71.3M
6 buyers · 0 sellers · 12 mo
Reddit crowd
60°
Warm · 1 mention this week
Filing reports
9
analyzed by SecBot
SecBot read BULLISH 4 reports · 90 days
Balance 0 bearish · 4 bullish oldest → newest, height = score
Avg score ·High conf. 4/4
Strongest BULLISH Scribe Therapeutics reported Q2 2026 results: net loss of $6.5M ($2.62/share) vs. $9.9M loss ($4.08/share) a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    6 insiders bought $71.3M at an average $15.08. No open-market sales. Price is 5% above their cost.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    36% below its 50-day average. New closing low $15.41 on Oct 23.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup call.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy4Buy5Hold1Sell0Strong Sell0
12-month targets · 4 analysts

Price is below the lowest target. Median implies +271%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 3, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 31, 2026HC Wainwright & Co.
INITIATE
INITIATEBuy
Aug 18, 2026Wells Fargo
INITIATE
INITIATEOverweight
Aug 18, 2026Leerink Partners
INITIATE
INITIATEOutperform
Aug 18, 2026Guggenheim
INITIATE
INITIATEBuy
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Short interest report
🔒 Fresh data, subscribers only
Sep 2, 2026 SEC
Scribe Therapeutics reported Q2 2026 results: net loss of $6.5M ($2.62/share) vs. $9.9M loss ($4.08/share) a year ago…
8-K — Impact 7/10
Sep 2, 2026 SEC
Scribe Therapeutics reported Q2 2026 collaboration revenue of $1.9M (down 61% YoY from $4.9M) and a net loss of $6.5M…
PRESS-RELEASE — Impact 7/10
Jul 29, 2026 SEC
A massive insider buying cluster at Scribe Therapeutics: six insiders (including directors OrbiMed, Carl Gordon, and…
CLUSTER — Impact 8/10
Jul 28, 2026 Insider
Aghazadeh Behzad bought 7,905 shares
Director @ $18.25 ($144.3K)
Jul 27, 2026 Insider
GORDON CARL L acquired 348,825 shares
Director
Jul 27, 2026 Insider
GORDON CARL L bought 1,000,000 shares
Director @ $15.00 ($15.0M)

Insider ledger

Form 4
$71.3M
bought · 6 insiders
$0
sold · 0 insiders
+5.4%
vs their $15.08 cost
DateInsiderTypeValue
Jul 28, 2026
Aghazadeh Behzad
Director
BUY$144.3K
Jul 27, 2026
GORDON CARL L
Director
CONVERT348,825 sh
Jul 27, 2026
GORDON CARL L
Director
BUY$15.0M
Jul 27, 2026
GORDON CARL L
Director
CONVERT2,065,672 sh
Jul 27, 2026
ORBIMED ADVISORS LLC
Director
BUY$15.0M
Jul 27, 2026
ORBIMED ADVISORS LLC
Director
CONVERT2,065,672 sh
Jul 27, 2026
ORBIMED ADVISORS LLC
Director
CONVERT348,825 sh
Jul 27, 2026
AH Bio Fund II, L.P.
10%+ Owner
CONVERT2,051,742 sh

Earnings setup

Estimates
−$1.03
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$1.03-$1.46–-$0.75—$3.7M
Next Q-$1.06-$1.55–-$0.51—$3.7M
Current FY-$5.59-$6.63–-$4.55—$11.6M
Next FY-$3.62-$4.47–-$3.11—$6.7M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Sep 30, 2026
Short interest
Short Interest: SCTX up 212% to 2.5M shares
Settlement 2026-09-30 | Days to cover: 3.58 | ≈13.03% of shares outstanding (est.)
Sep 2, 2026
Earnings
Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Scribe Therapeutics reports second quarter 2026 financial results and recent corporate highlights
Jul 27, 2026
Offering
Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
Scribe Therapeutics announces closing of initial public offering
Jul 24, 2026
Listing
New Listing: SCTX — Scribe Therapeutics Inc. - Common Stock
Listed on exchange Q
Reddit
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent comments
r/wallstreetbets Bullish 4d ago
Just bought the dip on SCTX after some small MRNA gains, gonna make 30% off this bad boy
All social signals and their track records

SecBot reports

9 filings · 6 bullish · 0 bearish · 3 neutral
All SCTX filing & press-release reports (9)